Our new partners join Perceptive Advisors and JW Funds with the same shared vision of Establishment Labs bringing innovation to market in the surgical aesthetics field.
New York, NY (PRWEB) April 17, 2017
Establishment Labs, a global medical device company focused on breast surgery technologies with a strong emphasis on product development and innovation, announced today that it has closed an $18 million financing round. Multiple investors participated, including Kilowatt Capital and Florence Capital Advisors.
"We are thrilled with the enthusiasm of the investment community in this oversubscribed round of funding," said Juan José Chacón Quirós, CEO of Establishment Labs. "This round of investment will support the process of launching Motiva Implants® and Puregraft® in some of the largest markets worldwide. We are grateful for the backing from our new and existing investors."
According to Nick Lewin from Crown Predator Holdings, "Our new partners join Perceptive Advisors and JW Funds with the same shared vision of Establishment Labs bringing innovation to market in the surgical aesthetics field. The company continues to rapidly scale, and this investment provides us the opportunity to build for the future and help Establishment Labs continue its high level of growth."
Over the last six months, Establishment Labs has received regulatory clearances in Russia, Australia, Saudi Arabia, Israel, Vietnam and Brazil -among others- and is currently in the process of scaling up production capacity at its new state of the art manufacturing plant in Costa Rica.
About Establishment Labs:
Establishment Labs is a global, privately held, breast implant and medical technology company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants (http://www.motivaimplants.com). Its CE-marked Motiva Implants® line of silicone breast implants utilizes medical-grade silicone and is subject to rigorous quality assurance testing throughout the manufacturing process. Motiva Implants® are sold in more than 60 countries worldwide. Puregraft®'s FDA cleared and CE-Marked technology provides plastic surgeons with purified fat for reinjection on the sterile field. The Puregraft® technology is used in hospitals and clinics around the world and provides physicians with confidence and convenience in fat grafting surgical procedures.
Crown Predator Holdings (CPH) invests in early and growth stage companies with an interest in special situations that do not easily fit into traditional investment categories. CPH leads and co-invests in transactions across all industries, capital structures, and styles. Through an extensive and global network of relationships and support, CPH seeks to add value as partners, not just as investors. Founded in 2006 and based in New York City, CPH is a family office led investment firm.